1) Hammond CB, Jelovsek FR, et al:Effects of long-term estrogen replacement therapy. Am J Obstet Gynecol 1979;133(5):525-536
2) Grady D, Rubin SM, et al:Hormone therapy to prevent disease and prolong life in post-menopausal women. Ann Intern Med 1992;117(12):1016-1037
3) Gambrell RD, Massey FM, et al:Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55(6):732-738
4) Persson I, Adami HO, et al:Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens:Results of a prospective study. BMJ 1989;298:147-151
5) Weiss NS, Ure CL, et al:Decreased risk of fractures of the hip and lower forearm with post-menopausal use of estrogen. N Engl J Med 1980;303(2):1195-1198
6) Schaad MA, Bonjour JP, et al:Evaluation of hormone replacement therapy use by the sales figures. Maturitas 2000;34:185-191
8) Wilson PWE, Garrison RJ, et al:Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50:The Framingham Study. N Engl J Med 1985;313:1038-1043
9) 小山嵩夫:我が国でどの位の女性がホルモン補充療法を受けているか. 日本更年期医学会雑誌 1995;3(2):256
10) 佐久間一郎, 和田博司, ほか:わが国閉経後女性へのホルモン補充療法の至適用法の検討:各種用法による血清脂質・リポ蛋白, 凝固・線溶系への影響の比較. 日本更年期医学会雑誌 2000;8 (suppl):138
11) Lock M:Menopause in cultural context. Exp Gerontol 1994;29:307-317
12) 後山尚久, 坪倉省吾, ほか:閉経後および術後不定愁訴症候群へのホルモン補充療法の臨床成績. 臨床婦人科産科 1993;47:437-440
13) Christiansen C, Christensen MS, Transbφl I:Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;i:459-461
14) The Postmenopausal Estrogen/Progestin Interventions (PEPI)Trial:Effect of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. JAMA 1995; 273(3):199-208
16) 石河 修, 角 俊幸, ほか:特集・更年期外来診療の実際-中高年女性と尿失禁. 産婦人科治療 1997;74(3):286-293
17) 進 純郎, 奥平さやか:中高年女性のwell-beingとホルモン療法(HRT) -尿失禁とHRT. 産婦人科治療 2000;81(6):666-670
18) Iosif CS, Batra S, et al:Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 1981;141:817-820
19) 本庄英雄, 岩佐弘一, ほか:老化, 痴呆に対するエストロゲンの効用. Modern Reproductive Medicine 2, エストロゲン-新しい視点からみた作用と臨床. 1999; pp130-139, メジカルビュー社, 東京
20) 後山尚久, 坪倉省吾, ほか:エストロゲン補充療法(ERT)の実際と問題点. Modern Reproductive Medicine 2, エストロゲン-新しい視点からみた作用と臨床. 1999; pp68-83, メジカルビュー社, 東京
21) Collaborative group on hormone factors in breast cancer:Breast cancer and hormone replacement therapy:Collaborative reanalysis of date from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059
22) 矢沢珪二郎:選択的エストロゲンレセプター調節剤(SERMs). Modern Reproductive Medicine 2, エストロゲン-新しい視点からみた作用と臨床. 1999;pp148-153, メジカルビュー社, 東京
23) Love R, Barden H, et al:Effect of tamoxifen on lumbar spine bone mineral density post-menopausal women after 5 years. Arch Intern Med 1994;154:2585-2588
24) Jordan V, Fritz N, Tormey D:Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 1987;47:624-630
26) Early Breast Cancer Trialists' Collaborative Group:Tamoxifen for early breast cancer:An overview of the randomized trials. Lancet 1998;351:1451-1467
27) Baker VL, Leitman D, Jaffe RB:Selective estrogen receptor modulators in reproductive medicine and biology. Obstet Gynecol Surv 2000;55 (7 suppl 2):S21-S47
28) Ettinger B, Black D, et al:Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene:Results from a 3 year randomized clinical trial. JAMA 1999;282:637-645
29) Davies GC, Huster WJ, et al:Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999;6:188-195
30) Boss S, Huster W, et al:Effects of raloxifene hydrochloride on the endometrium of post-menopausal women, Am J Obstet Gynecol 1997;177:1458-1464
31) Fugere P, Scheele W, et al:Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women. Am J Obstet Gynecol 2000;182:568-574
32) Kokcu A, Cetinkaya MB, et al:The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75-80
33) Di Carlo C, Palomba S, et al:Use of Leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. Fertil Steril 2001;75(2):380-384
34) van der Vies J:Pharmacological studies with (7 alpha, 17 alpha)17-hydroxy-7-methyl-19 norpregn 5(10)-en-20-yn-3. one(Org OD 14). Maturitas 1987; Suppl 1:15-24
35) Herschberger LG, Shipley EG, Meryer RH:Myotrophic activity of 19-nortestosterone and other osteroids determined by the modified levator muscle method. Proc Soc Exp Biol Med 1953;83:175-180
37) Ross LA, Alder EM:Tibolone and climacteric symptoms. Maturitas 1995;21(2):127-136
38) Genazzni AR, Facchinetti E et al:β-Lipoprotein and β-endorphin inphysiological and surgicalmenopause. J Endocrinol Invest 1981;4:375-378
39) Palacios S, Menendez C, et al:Changes in sex behaviour after menopause:Effects of tibolone. Maturitas 1995;22:155-161
40) Berning B, van Kuijk C, et al:Effects of withdrawal of HRT with tibolone on bone mineral density in early postmenopausal women. Date on Livial(tibolone). World Congress on Osteoporosis 1996
41) Lippuner K, Hanggi W, et al:Prevention of postmenopausal osteoporosis in a comparative study with tibolone, oral estradiol and transdermal estradiol. Date on Livial(tibolone). World Congress on Osteoporosis 1996
42) Castelo-Branco C, Casals E, et al:Two-year prospective and comparative study of the effects of tibolone on lipid pattern, behaviour of apolipoproteins AI and B. Menopause 1999;6(2):92-97
43) Ginsburg J, Prelevic G, et al:Clinical experience with tibolone (Livial(R)) over 8 years. Maturitas 1995;21:71-76
44) Genazzani AR, Benedek-Jaszmann LJ, et al:Org OD 14 and the endometrium. Maturitas 1991;13(3):243-251
45) Ginsburg J, Prelevic GM:Cause of vaginal bleeding in postmenopausal women taking tibolone. Maturitas 1996;24(1-2):107-110
46) Meuwissen JH, Wigerinck MA, Haverkorn MJ:Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995;21(2):121-125
47) Santiago P:Tibolone:What does tissue specific activity mean? Maturitas 2001;37:159-165
48) Tang B, Markiewicz L, et al:Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerasecan locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug(Org OD 14). J Steroid Biochem Mol Biol 1993;45(5):345-351
49) Gompel A, Kandouz M, et al:The effect of tibolone on proliferation differentation and apoptosis in normal breast cells. Gynecol Endocrinol 1997;11(suppl 1):77-79
50) Lafita FR, Garcia B:Effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly woman. Ann Intern Med 2000;132:244
51) 西沢良記:骨粗鬆症の診断と治療に関する調査. Osteoporosis Japan 2000;8(3):347-356
52) 中元秀友:骨粗鬆症へのCa製剤と活性型ビタミンD・カルシトニンの使用法. 臨床成人病2000;30(7):915-922
53) 西井易穂:ビタミンDの骨作用 "bone effect". Clinical Calcium 2000;10:192-199
55) Hirsch PF, Ganthier GF, et al:Thyroid hypocalcemia principle and recurrent laryngeal nerve injury as factors afrecting the response to parathyroidectomy in rats. Endocrinology 1963;73:244-252
56) Pearse AGE:The thyroid parenchymatous cells of baber, and nature and function of their C cell successors in thyroid, parathyroid and ultimo-branchial bodies. Calcitonin, Proceedings of the Symposium Thyrocalcitonin and the C Cells(Taylor S, ed). 1968;p98, Heinemann Medical Books, London
58) 若松英吉, 吉川靖三, ほか:骨粗鬆症の腰背痛に対するYM-11221(合成サケカルシトニン)の比較検討, 多施設によるYM-11221とエルカルシトニンの二重盲検比較試験. 医学のあゆみ 1990;152:261-282
60) Dam H:Cholesterinstoffwechsel in Huhnereiern und Huhnchen. Biochem Ztschr 1929;215:475-492
61) Dam H, Schonheyder F:Deficiency disease in chicks resembling scurvy, Biochem J 1934;28:1355-1359
62) Stenflo J:Vitamin K and the biosynthesis of prothrombin IV. Isolation of peptides containing prosthetic groups from normal prothrombin and the corresponding peptides from dicoumarol-induced prothrombin. J Biol Chem 1974;249:5527-5535
63) Esmon CT, Sadowski JA, Suttie JW:A new carboxylation reaction. The vitamin K-dependent incorporation of H14CO3-into prothrombin. J Biol Chem 1975;250:4744-4748
64) 朝倉英策, 御館靖雄, ほか:ビタミンKの歴史. Clinical Calcium 1999;9(7):8-12
65) Bouckaert JH:Fracture healing by vitamin K. Nature 1960;19:849
66) Pettifor JM, Benson R:Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J Pediatr 1975;86:459-462
67) Hauschka PV, Lian JB, Gallop PM:Direct identification of the calcium-binding amino acid γ-carboxyglutamate in mineralized tissue, Proc Natl Acad Sci U S A 1975;72:3925-3929
68) Price PA, Otsuka AA, ct al:Characterization of a γ-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci U S A 1976;73:1447-1451
69) Price PA, Willamson MK:Effects of warfarin on bone. J Biol Chem 1981;256:12754-12759
70) 青島宏枝, 串田一博:骨粗鬆症へのイプリフラボンとビタミンK2の使用法. 臨床成人病 2000; 30(7):931-935
71) Shiraki M, Shiraki Y, et al:Vitamin K2(menatetrenone)effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000;15:515-521
72) Ea-0167研究会:骨粗鬆症に対するEa-0167(menatetrenone)の臨床評価. 臨床評価1992; 20:45-100
73) Hart JP, Shearer MJ, et al:Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis. J Clin Endocrinol Metab 1985;60:1268-1269
75) Kaneki M, Mizuno Y, et al:Serum concentration of vitamin K in elderly women with involutiorial osteoporosis. Japan, J Geriatrics 1995;32:195-200
76) 金木正夫, 細井孝之, ほか:骨粗鬆症における血清ビタミンK2濃度の意義-著明な地域差と納豆摂取の影響, 大腿骨頸部骨折との関連に関する検討. 納豆の機能成分, 及び治療, 予防に関する研究. 1994;pp67-70, 社団法人日本工業技術振興協会, 東京
78) 平松和子, 猪熊茂子, 田中 治:膠原病患者の骨塩量減少に対するメナテトレノンの治療効果の検討. リウマチ科1999;21:323-330
79) 内山明好, 大澤光晴:ビタミンK. Modern Physician 2000;20(2):222-225
81) 白木正孝:ビタミンKによる治療効果の予測と判定. Clinical Calcium 1999;9(7):92-95
82) Fleisch HA:Bisphosphonates-preclinical aspects and use in osteoporosis. Ann Med 1997;29 (1):55-62
83) Sato M, Grasser W, et al:Bisphosponate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88(6):2095-2105
85) Inui Ishibashi O, et al:Cathepsin K antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem 1997;272(13):8109-8112
86) Salo J, Lehenkari P, et al:Removal of osteoclast bone resorption products by transcytosis. Science 1997;276(5310):270-273
87) Nesbitt SA, Horton MA:Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997;276(5310):266-269
88) David P, Nguyen H, et al:The bisphosphonate tiludronate is a potent irihibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res 1996;11(10):1498-1507
89) Schmidt A, Rutledge SJ, et al:Protein-tyrosine phosphatase activity regulates osteoclast formation and function inhibition by alendronate. Proc Natl Acad Sci U S A 1996;93(7):3068-3073
90) Murakami H, Takahashi N, et al:A possible mechanism of the specific action of bisphosphonates on osteoclasts-tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17(2):137-144
93) Ravn P, Clemmesen B, et al:The effect on bone mass and bone markers of different doses of ibandronate-a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis-a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19(5):527-533
95) Kodama Y, Nakayanla K, et al:Inhibition of bone resorption by pamidronate cannot restore normal gain in cortical bone mass and strength in tail-suspended rapidly growing rats. J Bone Miner Res 1997;12(7):1058-1067
96) Baumann BD, Wronski TJ:Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 1995;16(2):247-253
97) Tucci JR, Tonino RP, et al:Effect of three years of oral alendronate treatment in postmetnopausal women with osteoporosis. Am J Med 1996;101(5):488-501
98) Liberman UA, Weiss SR, et al:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The alendronate phase III osteoporosis treatment study group. N Engl J Med 1995;333(22):1437-1443
99) Devogelaer JP, Broll H, et al:Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women wit osteoporosis. Bone 1996;18(2):141-150
100) Black DM, Cummings SR, et al:Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 1996; 348(9041):1535-1541
101) Bolle HG, Downs R, Jr, et al:Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate elderly osteoporosis study centers. J Clin Endcrinol Metab 1997;82(1):265-274
102) Mosekilde L, Sogaard CH, et al:PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents(estrogen and bisphosphonate)-assessed in sexually mature, ovariectomized rats. Bone 1994;15(4):401-408
103) Orr-Walker B, Wattie DJ, et al:Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis, Clin Endocrinol 1997;46 (1):87-92
104) Wolfhagen FH, van Buuren HR, et al:Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997;26(2):325-330
105) Gulko PS, Mulloy AL:Glucocorticoid-induced osteoporosis:pathogenesis, prevention and treatment. Clin Exp Rheumatol 1996;14(2):199-206
106) Mulder H, Struys A:Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33(4):348-350
107) Eggelmeijer F, Papapoumlos SE, et al:Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996;39(3):396-402
108) Rizzoli R, Forni M, et al:Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 1996;18(6):531-537
110) Hortobagyi GN, Theriault RL, et al:Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocl 19 aredia breast cancer study group. N Engl J Med 1996;335(24):1785-1791
113) 中塚喜義:ビスホスホネート最近の話題. Clin Calcium 2000;10(3):249-254
114) Storm T, Thamsborg G, et al:Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322(18):1265-1271
116) 藤田拓男, 折茂'肇, ほか:退行期骨粗鬆症に対するアルファカルシドールを対照としたエチドロン酸二ナトリウム(EHDP)の二重盲検比較試験. 臨床評価 1993;21:261-302
117) Miller PD, Watts NB, et al:Cyclical etidronate in the treatment of postmenopausal osteoporosis:efficacy and safety after seven years of treatment. Am J Med 1997;103(6):468-476
118) Cummings SR, Black DM, et al:Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998;280(24):2077-2082
119) Hosking D, Chilvers CED, et al:Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998;338(8):485-492
120) Shiraki M, Kushida K, et al:A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporosis Int 1999;10(3):183-192
121) Clemmesen B, Ravn P, et al:A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095)in postmenopausal osteoporosis. Osteoporosis Int 1997;7(5):488-495
122) Mortensen L Charles P, et al:Risedronate increases bone mass in an early postmenopausal population-two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998; 83(2):396-402
123) Harris ST, Watts NB, et al:Effects of risedronate treatment on vertebral and nonvertcbral fractures in women postmenopausal osteoporosis-a randomized controlled trial. JAMA 1999;282 (14):1344-1352
124) 折茂 肇, 吉川靖三, ほか:原発性骨粗鬆症に対するインカドロネート(YM175)錠のアルファカルシドールを対照とした第III相多施設共同二重盲検比較試験. Osteoporosis Japan 1998;6 (4):815-843
125) Thiebaud D, Burckhardt P, et al:Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am Med 1997;103(4):298-307
126) 円妻進, 梶山梧朗:EBMに基づく高脂血症の治療. 医薬ジャーナル2000;36(10):2717-2722
127) 厚生省特定疾患, 「原発性高脂血症」調査研究班(垂井清一郎班長):我が国における高脂血症表現型の分類および血清脂質値と血管合併症発症の関連. 昭和61年度報告書. 1986;pp17-26
128) Schoonjans K, Staels B, et al:The peroxisome proliferator activated receptors(PPARS)and their effects on lipid metabolism and adipocyte difrerentiation. Biochini Biophys Acta 1996;1302:93-109
129) Schoonjans K, Peinado-Onsurbo J, et al:PPAR alpha and PPAR gamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996;15:5336-5348
131) Yamamoto A, Matsuzawa Y, et al:Effects of probucol on homozygous cases of familial hypercholesterolemia. Atherosclerosis 1983;48(2):157-166
132) 寺本民生:スタチン剤の特徴と臨床効果. 医薬ジャーナル1999;35(10):273-277
133) Endo A, Kuroda M, Tsujita Y:ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced byt Penicillum citrinum. J Antibiot (Tokyo) 1976;29:1346-1348
135) Koga T, Fukuda K, et al:Tissue selectivity of pravastatin sodium, lovastatm and simvastatin. The relationship between inhibition of de novo sterol synthesis and active drug concentrations in the liver, spleen and testis in rat. Eur J Biochem 1992;209:315-319
137) Sacks FM, Pfeffer MA, et al:The effect of pravastatin on corollary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl, J Med 1996;335:1001-1009
139) Pedersen TR, Berg K, et al:Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1996;156(18):2085-2092
141) Saito Y, Yoshida S, et al:Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparactive study. Arterioscler Thromb 1991;11(4):816-826
142) Fluvastatin研究会:高脂血症に対するFluvastatin(XU62~320)の臨床効果-3群間二重盲検比較法による用量検討試験. 臨床医薬1995;11(Suppl 1):155-180
143) Herd JA, Ballantyne CM, et al:Effects of fluvastatin in coronary atherosclerosis in patients with mild to moderate cholesterol elevations. (The lipoprotein and coronary atherosclerosis study (LCAS)). Am J Cardiol 1997;80(3):278-286
144) Serruys PW, Foley DP, et al:A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty:Final results of the fluvastatin angiographic restenosis(FLARE)trial Eur Heart J 1999;20:58-69
145) Riegger G, Abletshauser C, et al:The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999;144:263-270
146) 三井田孝, 星 勝治:内分泌・代謝疾患, 脂質代謝異常. 臨床薬物治療学-疾病の解説と薬の使い方. 2000;pp616-622, アークメディア, 東京
147) 大塚恭男, 木村雄四郎, 間中喜雄(編):東洋医学大事典. 1987, 講談社, 東京
148) 日本漢方医学研究所(編):総論. 漢方医学. 1990;pp17-21, 自然と科学社, 東京
149) 太田博明, 高松 潔, ほか:機能性月経困難症に対するvisual analogue scale(VAS)の有用性と芍薬甘草湯の鎮痛効果に関する検討. 産婦人科漢方研究のあゆみ1996;13:25-29
150) 柴田哲生, 盛本太郎, ほか:子宮筋Prostaglandin産生に及ぼす芍薬甘草湯の効果. 日本産科婦人科学会雑誌1996;48:321-327
151) 済木育夫:十全大補湯の癌転移抑制効果とその機序. 漢方医学2000;24(4):165-167
152) 安井敏之, 苛原 稔, ほか:婦人科癌における小柴胡湯の抗腫瘍効果及び作用機序に関する検討. 和漢医薬学雑誌1994;11:161167
153) 安井敏之, 苛原 稔, ほか:婦人科癌における小柴胡湯の抗腫瘍効果に関する検討. 和漢医薬学雑誌1994;11:346-347
154) 杉山 清:シスプラチンの副作用に対する十全大補湯の軽減効果ならびにその作用機序. 産婦人科漢方研究のあゆみ2000;17:5-13
155) 野口将道, 飯塚 進, ほか:更年期Hot Flush実験モデルにおける当帰芍薬散, 加味逍遙散, 桂枝茯苓丸の作用比較検討. 和漢医薬学雑誌1997;14:438-439
156) 金子 均, 小山崇夫, ほか:GnRH agonistによるラットの骨量減少に対する八味地黄丸の抑制効果. 日本更年期医学会雑誌1995;3:225-232
157) 趙 重文, 丁 宗鐵:西洋医のための漢方入門. 産婦人科治療2001;82(3):277-283